后循环与前循环卒中的功能结局是否不同
基于奥地利卒中单元登记的前瞻性数据,按牛津郡社区卒中项目分类分层,用倾向性评分匹配后循环卒中与前循环卒中患者各4604例。前循环卒中3个月功能结局优于后循环卒中(OR 1.19,95%CI 1.1-1.28,P<0.0001),尤其在后循环卒中发病至入院时间>270分钟或发病时间不明时;≤270分钟或接受重组组织型纤溶酶原激活剂治疗者两组无显著差异。
要点
- 前循环卒中3个月功能结局优于后循环卒中(OR 1.19,95%CI 1.1-1.28,P<0.0001)。
- 后循环卒中发病至入院时间>270分钟者功能结局更差(OR 1.34,95%CI 1.17-1.54,P<0.0001)。
- 发病至入院时间≤270分钟或接受溶栓治疗者,前后循环卒中功能结局无显著差异。
核心结论
- 后循环卒中在发病至入院时间>4.5小时或发病时间不明的患者中,功能结局较前循环卒中更差。
研究设计与样本
- 前瞻性纳入奥地利卒中单元登记(Austrian Stroke Unit Registry)的急性缺血性卒中患者,按牛津郡社区卒中项目分类(Oxfordshire Community Stroke Project Classification)根据梗死部位分层,采用倾向性评分匹配控制协变量不平衡,匹配卒中严重程度、重组组织型纤溶酶原激活剂治疗及人口学和血管危险因素。
- 共纳入90484例患者,匹配9208例(后循环卒中4604例/前循环卒中4604例),其中954例(每组477例)接受重组组织型纤溶酶原激活剂治疗。
主要发现
- 前循环卒中患者3个月功能结局较后循环卒中显著改善(OR 1.19,95%CI 1.1-1.28,P<0.0001)。
- 后循环卒中发病至入院时间>270分钟者功能结局更差(OR 1.34,95%CI 1.17-1.54,P<0.0001)。
- 后循环卒中发病至入院时间不明者功能结局更差(OR 1.26,95%CI 1.13-1.42,P<0.0001)。
- 发病至入院时间≤270分钟者,前循环卒中与后循环卒中功能结局无显著差异(1-180分钟:OR 0.92,95%CI 0.78-1.09,P=0.3554;181-270分钟:OR 1.04,95%CI 0.79-1.37,P=0.7689)。
- 接受重组组织型纤溶酶原激活剂治疗的患者中,后循环卒中与前循环卒中功能结局无显著差异。
临床怎么用
- 作者认为结果支持将后循环症状纳入院前患者分诊工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Posterior circulation stroke (PCS) account for 20% of all ischemic strokes. There is limited evidence whether functional outcome of PCS is comparable to that of anterior circulation stroke (ACS). We aimed to analyze whether 3-month functional outcome is different in PCS and ACS. Methods- Patients with acute ischemic stroke prospectively enrolled within the Austrian Stroke Unit Registry were stratified by infarct localization according to the Oxfordshire Community Stroke Project Classification. Propensity score matching was used to control for covariate imbalances and to match patients with PCS and ACS. Patients were matched for stroke severity, recombinant tissue-type plasminogen activator treatment, and demographic and vascular risk factors. Main outcomes were the distribution of modified Rankin Scale after 3 months and multiple proportional odds models to estimate the influence of the infarct localization on the functional outcome. Results- From a total of 90 484 patients enrolled within the Austrian Stroke Unit Registry, 9208 (4604 PCS/4604 ACS) were matched, of those 954 (477 in each group) were treated with recombinant tissue-type plasminogen activator. We detected a significant shift towards better 3-month functional outcome in patients with ACS compared with PCS (odds ratio [OR], 1.19; 95% CI, 1.1-1.28; P<0.0001). In particular, functional outcome was worse in PCS with onset-to-door-time >270 minutes (OR, 1.34; 95% CI, 1.17-1.54; P<0.0001) and in PCS with unknown onset-to-door-time (OR, 1.26; 95% CI, 1.13-1.42; P<0.0001); however, we did not detect any difference in functional outcome between ACS and PCS in patients with an onset-to-door-time ≤270 minutes (1-180 minutes: OR, 0.92, 95% CI, 0.78-1.09, P=0.3554; 181-270 minutes: OR, 1.04, 95% CI, 0.79-1.37, P=0.7689). In patients treated with recombinant tissue-type plasminogen activator, functional outcome was not significantly different between PCS and ACS. Conclusions- PCS was associated with worse outcome compared with ACS in patients arriving later than 4.5 hours at hospital or in those with unknown onset of symptoms. Our results urge for implementation of symptoms found in the posterior circulation into preclinical patient-triage tools.
引用
- Sommer P, Posekany A, Serles W, et al. Is Functional Outcome Different in Posterior and Anterior Circulation Stroke? Stroke. 2018. PMID: 30355215. doi:10.1161/STROKEAHA.118.021785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。